787
Views
0
CrossRef citations to date
0
Altmetric
Clinical Study

Lower serum insulin-like growth factor-1 levels are independently associated with anemia in patients undergoing maintenance hemodialysis

, , , , , , , , & ORCID Icon show all
Article: 2221130 | Received 10 Oct 2022, Accepted 30 May 2023, Published online: 05 Jul 2023

References

  • Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28(1):1–8.
  • Zuo L, Wang M, Hou F, et al. Anemia management in the China dialysis outcomes and practice patterns study. Blood Purif. 2016;42(1):33–43.
  • Succurro E, Arturi F, Caruso V, et al. Low insulin-like growth factor-1 levels are associated with anaemia in adult non-diabetic subjects. Thromb Haemost. 2011;105(2):365–370.
  • De Vita F, Maggio M, Lauretani F, et al. Insulin-like growth factor-1 and anemia in older subjects: the inchianti study. Endocr Pract. 2015;21(11):1211–1218.
  • Shih LY, Huang JY, Lee CT. Insulin-like growth factor I plays a role in regulating erythropoiesis in patients with end-stage renal disease and erythrocytosis. J Am Soc Nephrol. 1999;10(2):315–322.
  • Liu Y, Hu J, Tang R, et al. Association between the blood manganese (Mn) and hemoglobin in patients undergoing maintenance hemodialysis. J Trace Elem Med Biol. 2022;71:126947.
  • Liu Y, Wang L, Li S, et al. Associations between blood trace element levels and nutritional status in maintenance hemodialysis. J Ren Nutr. 2021;31(6):661–668.
  • Kidney Disease: improving Global Outcomes (KDIGO) CKDMBD Update Work Group. KDIGO 2017 clinical practice guide- line update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD- MBD). Kidney Int Suppl. 2017;2011(suppl):1–59.
  • Deicher R, Hörl WH. Hormonal adjuvants for the treatment of renal anaemia. Eur J Clin Invest. 2005;35(Suppl 3):75–84.
  • Correa PN, Axelrad AA. Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium: role of insulinlike growth factor 1. Blood. 1991;78(11):2823–2833.
  • Claustres M, Chatelain P, Sultan C. Insulin-like growth factor I stimulates human erythroid colony formation in vitro. J Clin Endocrinol Metab. 1987;65(1):78–82
  • Miyagawa S, Kobayashi M, Konishi N, et al. Insulin and insulin-like growth factor I support the proliferation of erythroid progenitor cells in bone marrow through the sharing of receptors. Br J Haematol. 2000;109(3):555–562.
  • Otake S, Sasaki T, Shirai T, et al. CLEC-2 stimulates IGF-1 secretion from podoplanin-positive stromal cells and positively regulates erythropoiesis in mice. J Thromb Haemost. 2021;19(6):1572–1584.
  • Butler AA, Yakar S, Gewolb IH, et al. Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comp Biochem Physiol B Biochem Mol Biol. 1998;121(1):19–26.
  • Kucic T, Copland IB, Cuerquis J, et al. Mesenchymal stromal cells genetically engineered to overexpress IGF-I enhance cell-based gene therapy of renal failure-induced anemia. Am J Physiol Renal Physiol. 2008;295(2):F488–96.
  • Suzuki J, Kaziro Y, Koide H. Synergistic action of R-Ras and IGF-1 on bcl-xL expression and caspase-3 inhibition in BaF3 cells: r -Ras and IGF-1 control distinct anti-apoptotic kinase pathways. FEBS Lett. 1998;437(1-2):112–116.
  • Hribal ML, Procopio T, Petta S, et al. Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic. J Clin Endocrinol Metab. 2013;98(2):E304–8.
  • Coyne DW, Fleming R. Will targeting interleukin-6 in the anemia of CKD change our treatment paradigm? J Am Soc Nephrol. 2021;32(1):6–8.
  • Palles C, Johnson N, Coupland B, et al. Identification of genetic variants that influence circulating IGF1 levels: a targeted search strategy. Hum Mol Genet. 2008;17(10):1457–1464.
  • Akahane K, Tojo A, Urabe A, et al. Pure erythropoietic colony and burst formations in serum-free culture and their enhancement by insulin-like growth factor I. Exp Hematol. 1987;15(7):797–802.
  • Jia T, Gama Axelsson T, Heimbürger O, et al. IGF-1 and survival in ESRD. Clin J Am Soc Nephrol. 2014;9(1):120–127.
  • Iglesias P, Díez JJ, Fernández-Reyes MJ, et al. Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. Am J Kidney Dis. 1998;32(3):454–463.
  • Chu LW, Lam KS, Tam SC, et al. A randomized controlled trial of low-dose recombinant human growth hormone in the treatment of malnourished elderly medical patients. J Clin Endocrinol Metab. 2001;86(5):1913–1920.
  • Soliman AT, De Sanctis V, Yassin M, et al. Growth and growth hormone–insulin like growth Factor -I (GH-IGF-I) axis in chronic anemias. Acta Biomed. 2017;88(1):101–111.
  • Kim DH, Kim TY, Kim SM, et al. IGF-1 is an independent risk factor for anemia in diabetic pre-dialysis patients. Korean J Intern Med. 2007;22(3):186–191.